Skip to main content
Medical Science Monitor: International Medical Journal of Experimental and Clinical Research logoLink to Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
. 2021 Mar 25;27:e932331-1. doi: 10.12659/MSM.932331

Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway

Fengli Zhang 1,2, Huixiao Chen 2, Jing Du 2, Bin Wang 2, Lixiao Yang 2,
PMCID: PMC8009266  PMID: 33762564

Retraction Notice:

An editorial decision has been made to retract this manuscript due to breach of publishing guidelines, following the identification of non-original and manipulated figures.

Reference

  1. Zhang Fengli, Chen Huixiao, Du Jing, Wang Bin, Yang Lixiao. Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Med Sci Monit. 2018;24:6093–6101. doi: 10.12659/MSM.909745. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

Articles from Medical Science Monitor : International Medical Journal of Experimental and Clinical Research are provided here courtesy of International Scientific Information, Inc.

RESOURCES